Safety and activity of the multikinase inhibitor sorafenib in heavily pretreated patients with refractory/relapsed malignant lymphomas: Final results of a phase II study. This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback